103 results about "Conotoxin" patented technology

The invention relates to linear y-carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.

The present invention is directed to β-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the β-superfamily conotoxin peptides and encoding β-superfamily conotoxin propeptides, as well as the β-superfamily conotoxin propeptides.

The invention provides an anti-wrinkle eye cream, wherein natural marine conotoxin is rich in various amino acids, the combined action of the natural marine conotoxin and dipeptide diaminobutyroyl benzylamide diacetate can improve ocular microcirculation and alleviate dark eye circles, and inhibit contraction of ocular muscles, thereby achieving the effect of reducing wrinkles; by jointing using hydrolyzed wheat protein, hydrolyzed collagen and hydrolyzed soybean protein, and utilizing compounding of the collagen, a moisturizing protective film is formed on a skin surface, so as to enhance theadherence of matrix outside epithelial cells, maintain a compact state of epithelial lipid monolayer molecular film, increase the level of cellular protein, and promote the synthesis of the collagen,thereby synergistically enhancing the anti-wrinkle effect; and ceramide, tocopherol acetate and saccharomyces lysate promote the skin metabolism, prevent pigment deposition, improve skin elasticity,lock moisture in the skin, repair skin barriers, and moisten the skin.

The invention relates to the field of polypeptide drugs, in particular to a conotoxin polypeptide, a preparation method and an application thereof, and especially relates to the conotoxin polypeptide acting on muscle-type nicotinic acetylcholine receptors. The amino acid sequence of the conotoxin polypeptide is HPA. The experimental results indicates that the conotoxin polypeptide HPA can act on the muscle-type nicotinic acetylcholine receptors to effectively inhibit the acetylcholine receptors, and can serve as antagonists of the muscle-type nicotinic acetylcholine receptors. The conotoxin polypeptide HPA can be used for preparing anti-wrinkle cosmetics, is broadly used and has good economic and social effects.

This invention relates to novel α-conotoxin-like peptides comprising the following sequence of amino acids: Xaa1CCSXaa2Xaa3Xaa4CXaa5Xaa6Xaa7Xaa8Xaa9Xaa10Xaa11C—NH2 in which Xaa1 is G or D; Xaa3 is proline, hydroxyproline or glutamine; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is proline, hydroxyproline or glutamine; Xaa10 is aspartate, glutamate or γ-carboxyglutamate; Xaa11 is optionally absent; and the C-terminus is optionally amidated, with the proviso that the peptide is not α-conotoxin Ep1 or α-conotoxin Im1. The peptides are useful in the treatment or prevention of pain, in recovery from nerve injury, and in the treatment of painful neurological conditions such as stroke.

The present invention provides the GST fusion expression and application of a kind of conotoxin MVII A gene. GST-CTX MVII A recombinant fusion protein is cloned and expressed in colibacillus, and through GST affinity chromatography purified GST-CTX MVII A fusion protein is obtained. The fusion protein the present invention obtains may be applied in preparing medicine for treating intractable painof cancer and AIDS patient in the late stage, preparing analgesic for treating post-operation acute pain, pain of burn, biliary colic, intractable neuralgia, etc., and preparing medicine with nerve protecting function for treating cerebral ischemia and cerebral damage. The obtained fusion protein has relatively great molecular weight and relatively long half life in body and may be enzyme incisedto obtain active omiga-conotoxin MVII A small peptide for direct medicine development.

The invention relates to a new South China Sea conus M-superfamily toxin gene Lt3.2 and a polypeptide sequence lt3b coded by the same, and the application of the polypeptide in preparing tool medicine for the neurobiological research and analgesic drugs. By constructing cDNA library, the new M-superfamily toxin gene is obtained by cloning the South China Sea conotoxin, the cDNA sequence of Lt3.2 is shown by Sq. (400) 1 in the sequences table. As for the polypeptide (conotoxin lt3b) coded by the gene, the amino acid sequence of the precursor peptide is shown in Sq. (400) 2 of the sequences table, and the amino sequence of the presumed mature peptide is shown in Sq. (400) 3 of the sequences table. The neurotoxin lt3b of the invention can increase the opening current of the sodium channel and has an effect of abirritation. The neurotoxin lt3b can also be used for preparing tool medicine for the neurobiological research and analgesic agent.

The invention discloses seven alpha type conotoxin peptides and applications thereof. The peptide I has an amino acid sequence shown as the sequence 7 in a sequence table, and the last amino acid residue is amidated; the peptide II has an amino acid sequence shown as the sequence 8 in the sequence table, and the last amino acid residue is amidated; the peptide III has an amino acid sequence shownas the sequence 9 in the sequence table, and the last amino acid residue is amidated; the peptide IV has an amino acid sequence shown as the sequence 10 in the sequence table, and the last amino acidresidue is amidated; the peptide V has an amino acid sequence shown as the sequence 11 in the sequence table, and the last amino acid residue is amidated; the peptide VI has an amino acid sequence shown as the sequence 12 in the sequence table, and the last amino acid residue is amidated; and the peptide VII has an amino acid sequence shown as the sequence 13 in the sequence table. Proved by determination of activity, the seven peptides shown as a general formula I have an analgesic effect, wherein alpha type conotoxin peptides T-1, T-2, T-3 and T-4 have remarkable analgesic activity, and thealpha type conotoxin peptides T5-T7 also have remarkable analgesic activity, and the application value on the aspect of analgesia is achieved.